OncoEMR®

IDENTIFYING PATIENTS WITH HR+ HER2- EARLY BREAST CANCER

INSTRUCTIONS

Your electronic health record may have reporting capabilities that can be used to identify select patients with HR+ HER2- early breast cancer. Consult your organization if administrative user rights are required to access the reporting solutions. Below are inclusion criteria that could be used to identify patients with early breast cancer.

PLEASE NOTE: A custom report may yield most insights into this patient population.

Inclusion Criteria[1]:

Primary Diagnosis:

C50.011	C50.012	C50.019	C50.111	C50.112	C50.119	C50.211	C50.212	C50.219	C50.311
C50.312	C50.319	C50.411	C50.412	C50.419	C50.511	C50.512	C50.519	C50.611	C50.612
C50.619	C50.811	C50.812	C50.819	C50.911	C50.912	C50.919	C50.01	C50.11	C50.21
C50.31	C50.41	C50.51	C50.61	C50.81	C50.91				

NOT

Secondary Neoplasm:

C78.00	C78.01	C78.02	C78.1	C78.2	C78.30	C78.39	C78.4	C78.5	C78.6
C78.7	C78.80'	C78.89 OR C79.00		C79.01	C79.02	C79.10	C79.11	C79.19	C79.2
C79.31	C79.32	C79.40	C79.49	C79.51	C79.52	C79.60	C79.61	C79.62	C79.70
C79.71	C79.72	C79.89	C79.82	C79.9					

The information provided herein is not intended to establish compliance with any accreditation, regulatory, or institutional requirements. Healthcare institutions remain responsible for ensuring that their own policies, procedures, systems, and practices satisfy applicable requirements. Healthcare professionals should rely on their own independent clinical judgment when making treatment decisions. Healthcare institutions and providers are solely responsible for evaluating, implementing, and using any EHR tools or related content and should exercise their own independent judgment in doing so. Information provided herein may be updated, modified, or withdrawn at any time and is provided without any representation or warranty as to its accuracy, completeness, or fitness for a particular purpose.

The instructions included in this brochure are applicable to the OncoEMR platform and **is not intended to apply** to any other software platforms. OncoEMR is a registered trademark of Flatiron Health.

For more information on how the Novartis Health Information Technology Team can collaborate with your organization to identify shared priorities, please email: HIT.Novartis@novartis.com.

1. CMS.gov. Centers for Medicare & Medicaid Services. ICD-10. Accessed May 5, 2026. https://www.cms.gov/medicare/coding-billing/icd-10-codes

NOVARTIS

IDENTIFYING PATIENTS WITH HR+ HER2- EARLY BREAST CANCER

INSTRUCTIONS (continued)

AND

Gene Expression Profile Procedures:

Oncotype DX: 81519[1]	Breast Cancer Index: 81518[3]
Prosigna CPT: 81520[2]	MammaPrint: 81523[4]

AND

Lab components

HR+ (ER receptor/PR receptor) ER/PR
HER2-

AND

Nodal Status/Staging TNM[5]

AJCC Anatomical Staging	TN (M0)
Stage IIA	**T0N1**
	T1N1
	T2N0
Stage IIB	**T2N1**
	T3N0
Stage IIIA	**T0N2**
	T1N2
	T2N2
	T3N1
	T3N2
Stage IIIB	**T4N0**
	T4N1
	T4N2
Stage IIIC	**Any TN3**

AND

CPT® codes

19301 Mastectomy, partial[6]
19306 Mastectomy, urban type[7]
19303 Mastectomy, simple complete[8]
19305 Mastectomy, radical[9]
19307 Mastectomy, modified radical[10]

1. Centers for Medicare & Medicaid Services. Billing and coding: MolDX: Oncotype DX® Breast Cancer Assay. CMS.gov. Accessed October 2, 2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=54480 **2.** Centers for Medicare & Medicaid Services. Billing and coding: MolDX: Breast Cancer Assay: Prosigna®. CMS.gov. Accessed October 2, 2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56949 **3.** Centers for Medicare & Medicaid Services. Billing and coding: MolDX: Breast Cancer Index® (BCI) Gene Expression Test. CMS.gov. Accessed October 2, 2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56335&LCDId=37913 **4.** Centers for Medicare & Medicaid Services. Billing and Coding: MolDX: MammaPrint. CMS.gov. Accessed October 2, 2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=53104 **5.** Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III, eds. AJCC Cancer Staging Manual. 7th Edition. American Joint Committee on Cancer; 2010. Accessed October 2, 2026. https://www.facs.org/media/j30havyf/ajcc_7thed_cancer_staging_manual.pdf **6.** Codify by AAPC. CPT® 19301, Under Mastectomy Procedures. AAPC. Accessed October 2, 2026. https://www.aapc.com/codes/cpt-codes/19301 **7.** Codify by AAPC. CPT® 19306, Under Mastectomy Procedures. AAPC. Accessed October 2, 2026. https://www.aapc.com/codes/cpt-codes/19306 **8.** Codify by AAPC. CPT® 19303, Under Mastectomy Procedures. AAPC. Accessed October 2, 2026. https://www.aapc.com/codes/cpt-codes/19303 **9.** Codify by AAPC. CPT® 19305, Under Mastectomy Procedures. AAPC. Accessed October 2, 2026. https://www.aapc.com/codes/cpt-codes/19305 **10.** Codify by AAPC. CPT® 19307, Under Mastectomy Procedures. AAPC. Accessed October 2, 2026. https://www.aapc.com/codes/cpt-codes/19307

CPT is a registered trademark of the American Medical Association.

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2026 Novartis